EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY-NC 4.0

Percutaneous left atrial appendage closure following catheter ablation therapy of atrial fibrillation: outcomes stratified by bleeding risk – a sub-analysis of the OPTION study

Karen P Phillips iD, Devi G Nair iD, Lucas V A Boersma iD, Rahul N Doshi iD, Jeff S Healey iD, Wael A Jaber iD, Moussa Mansour iD, Vivek Y Reddy iD, Claudio Tondo iD, Andrea Natale iD, Aravin Sukumar iD, Krystal Leger und 3 weitere

Europace · 02.06.2026 · 28 (6)

DOI: 10.1093/europace/euag093 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Europace, online erschienen am 02.06.2026. Verfasst von Karen P Phillips und 14 weiteren Autor:innen. Beteiligte Einrichtung: The Brisbane AF Clinic, Greenslopes Private Hospital, Suite 23, Greenslopes Specialist Centre, Newdegate Street, Greenslopes, Brisbane, Queensland 41…. Hauptthemen laut MEDLINE: Atrial Appendage, Atrial Fibrillation, Catheter Ablation, Hemorrhage. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Boston Scientific.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Concerns have been raised over the safety and necessity of continuing oral anticoagulation (OAC) in patients following catheter ablation for atrial fibrillation (AF). OPTION demonstrated the safety and efficacy of left atrial appendage closure (LAAC) in a post-ablation population. We sought to analyse the impact of baseline bleeding risk, per HAS-BLED scores, on the outcomes for patients in a pre-specified sub-analysis. Methods and results Patients with AF and high stroke risk undergoing catheter ablation were randomly assigned to LAAC vs. OAC in OPTION and were stratified by HAS-BLED score: 0, 1, 2, ≥3. OPTION enrolled 1600 patients (CHA2DS2-VASc score: 3.5 ± 1.3; HAS-BLED score: 1.2 ± 0.8); randomized 1:1 to ablation/LAAC or ablation/OAC. Primary effectiveness (all-cause death/stroke/systemic embolism) and safety (bleeding composite) endpoints were directionally similar in HAS-BLED subgroups; both thromboembolic and bleeding event rates were higher in patients with increasing HAS-BLED score. A significant reduction in primary safety bleeding events was noted in favour of LAAC across HAS-BLED subgroups, with more striking reductions noted for lower HAS-BLED scores of 0 (n = 265; hazard ratio: 0.25; 95% confidence interval: 0.20, 0.50) and 1 (n = 890; hazard ratio: 0.41, 95% confidence interval: 0.27–0.61).

Conclusion

Regardless of bleeding risk, LAAC is comparable to OAC in stroke protection while demonstrating greater freedom from bleeding in a post-ablation AF population, even in patients with low HAS-BLED scores. The OPTION study highlights an opportunity to mitigate future bleeding risk with a strategy of LAAC after ablation in patients deemed at high risk of stroke according to clinical guidelines. Trial registration number NCT03795298

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial AppendageAtrial FibrillationCatheter AblationHemorrhageLeft Atrial Appendage ClosureStrokeAgedFemaleHumansMaleMiddle AgedAnticoagulantsRisk AssessmentRisk FactorsThromboembolismTime FactorsTreatment Outcome

Stichwörter der Autor:innen

AnticoagulationAtrial fibrillationBleedingLeft atrial appendage closure

Substanzen

Anticoagulants

Autor:innen und Institutionen

  • The Brisbane AF Clinic, Greenslopes Private Hospital, Suite 23, Greenslopes Specialist Centre, Newdegate Street, Greenslopes, Brisbane, Queensland 4120, Australia.
  • Cardiac Electrophysiology Division, St. Bernards Medical Center & Arrhythmia Research Group, Jonesboro, AR, USA.
  • Cardiology Department, St. Antonius Hospital, Nieuwegein and UMC, Amsterdam, The Netherlands.
  • Cardiac Electrophysiology Division, Arizona State University John Schufeldt School of Medicine and Advanced Medical Engineering, Scottsdale, AZ, USA.
  • Department of Cardiac Electrophysiology, McMaster University, Hamilton, ON, Canada.
  • Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.

ORCID-Profile: Karen P Phillips, Devi G Nair, Lucas V A Boersma, Rahul N Doshi, Jeff S Healey, Wael A Jaber, Moussa Mansour, Vivek Y Reddy, Claudio Tondo, Andrea Natale, Aravin Sukumar

Förderung

  • Boston Scientific

Zitieren

APA

Phillips, K. P., Nair, D. G., Boersma, L. V. A., Doshi, R. N., Healey, J. S., Jaber, W. A., Mansour, M., Reddy, V. Y., Tondo, C., Natale, A., Sukumar, A., Leger, K., Christen, T., Sutton, B. S., & Wazni, O. M. (2026). Percutaneous left atrial appendage closure following catheter ablation therapy of atrial fibrillation: outcomes stratified by bleeding risk – a sub-analysis of the OPTION study. Europace, 28(6). https://doi.org/10.1093/europace/euag093

Vancouver

Phillips KP, Nair DG, Boersma LVA, Doshi RN, Healey JS, Jaber WA, et al. Percutaneous left atrial appendage closure following catheter ablation therapy of atrial fibrillation: outcomes stratified by bleeding risk – a sub-analysis of the OPTION study. Europace. 2026;28(6). doi:10.1093/europace/euag093

BibTeX
@article{Phillips2026,
  author = {Phillips, Karen P and Nair, Devi G and Boersma, Lucas V A and Doshi, Rahul N and Healey, Jeff S and Jaber, Wael A and Mansour, Moussa and Reddy, Vivek Y and Tondo, Claudio and Natale, Andrea and Sukumar, Aravin and Leger, Krystal and Christen, Thomas and Sutton, Brad S and Wazni, Oussama M},
  title = {Percutaneous left atrial appendage closure following catheter ablation therapy of atrial fibrillation: outcomes stratified by bleeding risk – a sub-analysis of the OPTION study},
  journal = {Europace},
  year = {2026},
  volume = {28},
  number = {6},
  doi = {10.1093/europace/euag093}
}
Kostenlos starten →